Cubist- Nothing Square About Its Fight To Prevent Hospital Infections ( CBST )

Cubist Pharmaceuticals (CBST )  has moved up recently on increasing stock volume and concerns over hospital aquired infections. CBST closed Friday at 43.81.

   CBST which is marketing Dificid with Optimer, is also developing a drug for C. difficile- associated diarrhea. The treatment which is in the second of three phases of testing generally required for approval.

   This past week the company opened a new 104,000 sf research and development facility.Cubist held an official opening ceremony for the R&D facility with speakers including company President and CEO Michael Bonney and special guest U.S. Senator Scott Brown.

“As we celebrate our 20^th anniversary this year, it is our belief that this state-of-the-art R&D facility will be at the center of a wave of future growth and innovation for Cubist,” said Mr. Bonney. “We look forward to many years of translating exciting science into real therapeutic options for patients in the acute care and hospital environment.”

Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.